Guardant Health Inc
GH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$67.00 | Ggk | Jqbpytgyp |
Guardant Health Earnings: Firm Reaps Volume Growth Benefits as Liquid Biopsy Trends Continue
No-moat Guardant Health posted strong second-quarter results that were about in line with our expectations. Solid volume growth drove revenue up 26% year over year and pushed management to lift full-year guidance. While we have slightly raised our full-year 2023 revenue growth forecast on a strong first-half performance, we maintain our longer-term growth assumptions, and therefore there is no material change to our $63 fair value estimate. Shares remain significantly undervalued at current prices.